deltatrials
Completed PHASE1/PHASE2 NCT00096486

Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer

A Phase I/II Trial of Fixed Doses of Daily Gefitinib With Escalating Doses of Daily RAD001 in Advanced Non-Small Cell Lung Cancer

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Lung Cancer
Interventions everolimus gefitinib
Updated 6 times since 2017 Last updated: Dec 15, 2015 Started: May 31, 2004 Primary completion: Jul 31, 2010 Completion: Jul 31, 2010

This PHASE1/PHASE2 trial investigates Lung Cancer and is currently completed. Memorial Sloan Kettering Cancer Center leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
  • National Cancer Institute (NCI)
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States